



Hepatocellular Carcinoma: Advances and Challenges in Research and Treatment

Guest Editor:

Dr. Huei-Lung Liang

Department of Radiology,
Kaohsiung Veterans General
Hospital, 386 Dazhong 1st Rd,
Kaohsiung 813, Taiwan

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide. Although the etiology of viral-hepatitis-related HCC has decreased due to the deployment of aggressive medication and/or vaccines, the etiologies of alcoholic- or nonalcoholic-fatty-liver-disease-related HCC are increasing. The importance of the clinical prevention and management of HCC still cannot be overstated. The new version of the BCLC guidelines recommends corresponding treatment strategies and clinical-outcome estimations for different stages of the disease. However, there still remain other unrecommended treatment modalities which may be beneficial, especially for the advanced HCC patients.

This Special Issue will reflect the recent advances in the research and treatment of HCC, including surgical resection, liver transplant, image-guided tumor ablation, conventional/drug-eluting chemoembolization, Y-90 radioembolization, new regimens of hepatic arterial infusion chemotherapy, proton beam radiotherapy, target/immunotherapy, and/or combination therapy.

Dr. Huei-Lung Liang
Guest Editor





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI